TECH Financials Bio-Techne

10 years of revenue, profit, cash flow and balance-sheet history through FY2026, from SEC filings — with a computed, factual read of the trend. Updated Oct 31, 2026, 11:19 UTC Overview →

Growth & profitability

Revenue has grown 5.5% per year over the past 5 years.
Net income has grown in line with revenue (5.4% vs 5.5% per year).
Operating margin has contracted, at 20.7% in the latest year.
Free cash flow has declined 3.1% per year over the past 5 years.

Financial health

Operating income covered interest expense 26× in the latest year.

Shareholder returns

Dividends have been paid for 10 consecutive years, consuming 27.4% of earnings and 19.0% of free cash flow.
The dividend has grown 0.1% per year over the past 5 years.

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key annual figures

FY	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
2026	$1.2B	$182M	65.8%	20.7%	8.6%	7.0%	$263M	—	$265M
2025	$1.2B	$73M	64.8%	8.4%	3.8%	2.9%	$257M	—	$162M
2024	$1.2B	$168M	66.4%	17.8%	8.1%	6.2%	$236M	—	$152M
2023	$1.1B	$285M	67.7%	26.3%	14.5%	10.8%	$216M	—	$181M
2022	$1.1B	$263M	68.4%	26.8%	15.5%	11.5%	$280M	—	$173M
2021	$931M	$140M	68.0%	25.5%	8.9%	6.2%	$308M	—	$199M
2020	$739M	$229M	65.4%	21.3%	16.6%	11.3%	$153M	—	$147M
2019	$714M	$96M	66.3%	20.5%	8.2%	5.1%	$156M	—	$101M
2018	$643M	—	67.2%	21.2%	0.0%	0.0%	$149M	—	$122M
2017	$563M	—	66.5%	21.4%	0.0%	0.0%	$129M	—	$92M

Revenue & net income

RevenueNet income

Margins (gross / operating / net)

GrossOperatingNet

Return on equity & assets (ROE / ROA)

ROEROA

Free cash flow (CFO − capex, quarterly)

Free cash flow

Cash vs total debt

CashTotal debt

Cash flow: operating / investing / financing

OperatingInvestingFinancing

Key quarterly figures

Quarter	Revenue	Net income	Gross M	Op M	ROE	ROA	FCF	Total debt	Cash
Jun '26	$321M	$55M	65.8%	23.1%	2.6%	2.1%	$87M	—	$265M
Mar '26	$311M	$51M	66.9%	24.2%	2.4%	2.0%	$78M	—	$210M
Dec '25	$296M	$38M	64.6%	18.4%	1.9%	1.5%	$76M	—	$173M
Sep '25	$287M	$38M	65.6%	16.6%	—	1.5%	$22M	—	$145M
Jun '25	$317M	-$18M	62.7%	-7.5%	-0.9%	-0.7%	$93M	—	$162M
Mar '25	$316M	$23M	67.9%	12.2%	1.1%	0.9%	$31M	—	$141M
Dec '24	$297M	$35M	65.3%	16.0%	1.7%	1.3%	$78M	—	$178M
Sep '24	$289M	$34M	63.2%	13.8%	1.6%	1.2%	$55M	—	$188M
Jun '24	$306M	$41M	66.4%	15.0%	2.0%	1.5%	$58M	—	$152M
Mar '24	$303M	$49M	67.4%	22.1%	2.4%	1.8%	$65M	—	$140M
Dec '23	$273M	$27M	64.8%	13.9%	1.4%	1.0%	$68M	—	$130M
Sep '23	$277M	$51M	66.9%	20.2%	2.6%	1.9%	$46M	—	$149M
Jun '23	$301M	$75M	67.9%	31.4%	3.8%	2.9%	$73M	—	$181M
Mar '23	$294M	$70M	68.7%	27.3%	3.7%	2.7%	$39M	—	$127M
Dec '22	$272M	$50M	67.5%	25.0%	2.7%	2.1%	$58M	—	$165M
Sep '22	$270M	$90M	66.6%	20.9%	5.1%	3.8%	$47M	—	$165M
Jun '22	$288M	$62M	69.5%	28.0%	3.6%	2.7%	$89M	—	$173M
Mar '22	$290M	$60M	69.4%	31.1%	3.5%	2.6%	$58M	—	$161M
Dec '21	$269M	$72M	68.2%	23.2%	4.2%	3.1%	$91M	—	$212M
Sep '21	$258M	$69M	66.4%	24.5%	4.2%	3.0%	$42M	—	$196M

Valuation over time

How the market has priced TECH against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

The price-to-earnings ratio has risen from 44.3× (Mar '23) to 62.8× (Nov '26).
The price-to-sales ratio has fallen from 10.5× (Mar '23) to 9.4× (Nov '26).
The dividend yield has risen from 0.4% (Mar '23) to 0.4% (Nov '26).

Price / earnings (P/E)

P/E

Price / sales (P/S)

P/S

Dividend yield (%)

Dividend yield %

Frequently asked questions

Is TECH growing its revenue and profit?

Over the past 5 years, Bio-Techne's revenue has grown 5.5% per year, and net income grown 5.4% per year. These are computed facts, not advice.

How much debt does TECH have?

As of FY2026, Bio-Techne reported — of total debt against $265M of cash; operating income covered interest expense 26×.

What is TECH's profit margin?

In FY2026, gross margin was 65.8%, operating margin 20.7%, and net margin 15.0%.

What is TECH's P/E ratio?

Bio-Techne's P/E (TTM) is 62.76 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the TECH stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 62.8× as of Nov '26) can differ. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.